Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/21161
Title: Assessing global and regional Aβ-amyloid deposition in the brain with multiple Aβ-tracers using the Centiloid scale
Austin Authors: Villemagne, Victor L ;Burnham, Samantha;Bourgeat, Pierrick;Dore, Vincent;Laws, Simon;Salvado, Olivier;Fripp, Jurgen;Martins, Ralph;Masters, Colin;Rowe, Christopher C 
Affiliation: Austin Health, Heidelberg, Victoria, Australia
Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia
CSIRO - AEHRC Brisbane Australia
CSIRO - AEHRC Melbourne Australia
Edith Cowan University Perth Australia
Florey Institute Melbourne Australia
McCusker Alzheimer'S Research Foundation Nedlands, Perth Australia
Issue Date: 1-May-2019
Date: 2019
Publication information: Journal of Nuclear Medicine 2019; 60 (Suppl 1): 248-248
Abstract: Background: The aim of the study was to evaluate if Centiloids (CL) generated with different Aβ tracers yielded similar rates of Aβ accumulation, validating its use in multicenter, multitracer anti-Aβ therapeutic trials. Methods: We used longitudinal Aβ imaging data from the AIBL and ADNI studies to calculate the rates of global and regional Aβ-amyloid deposition. We analyzed 485 participants from AIBL and ADNI (321 HC; 135 MCI; 29 AD) with 3 or more Aβ imaging assessments. While AIBL participants underwent Aβ imaging with PiB and NAV4694 (n=220, median follow-up of 4.8 -range 2.5-10.6- years), or flutemetamol (FLUTE, n=94, median follow-up of 3.2 -range 3.0-3.8- years), ADNI participants underwent Aβ imaging with florbetapir (FBP, n=171, median follow-up of 4.1 -range 2.9-5.7 - years). CL were generated using the CL cortical and whole cerebellum masks. FBP SUVR were first generated using a white matter mask and then converted to whole cerebellum before the CL transformation. Aβ accumulation was derived from the slope of the linear regression plots, and rates of accumulation were calculated from the time it took to go from a threshold 20 CL (Aβ-) to 100 CL (mean levels of Aβ+AD). Results: Of 485 initial participants, 417 (86%) (270 HC; 118 MCI; 29 AD) showed positive rates of Aβ accumulation over 3 or more assessments. Irrespective of the Aβ tracer used, Aβ deposition spans more than two decades, averaging 22.7±3.9 (mean±SD) years to go from a threshold of 20 CL to 100 CL. Rates of Aβ accumulation were 3.8 CL/yr (5%/yr) for PiB/NAV, 3.6 CL/yr (5%/yr) for FLUTE and 3.0 CL/yr (4%/yr) for FBP, respectively, averaging 3.5±0.4 CL/yr (4.3%/yr) when all tracers are considered together. The regional assessment showed fastest Aβ accumulation in the posterior cingulate/precuneus and frontal areas, and slowest in the hippocampus. Conclusions: Aβ-amyloid deposition is a slow and protracted process, extending for more than two decades. Centiloids can be used to combine longitudinal Aβ imaging data obtained with different Aβ tracers.
URI: https://ahro.austin.org.au/austinjspui/handle/1/21161
http://jnm.snmjournals.org/content/60/supplement_1/248.short
ORCID: 0000-0003-3910-2453
Journal: Journal of Nuclear Medicine
Type: Journal Article
Subjects: Aβ-amyloid deposition
Centiloids
Aβ tracers
Appears in Collections:Journal articles

Show full item record

Page view(s)

58
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.